FTX-6058 and Pociredir showed strong early sickle cell data, but FDA’s PRC2 class-risk view after Tazverik’s blood-cancer signal ended Fulcrum’s program. Fulcrum did not lose FTX-6058 and pociredir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results